FULL PAPER

Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix: a retrospective analysis from a single institution

Yoshino K, Nagai Y, Toita T, Kudaka W, Ariga T, Shimoji Y, et al. Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix: a retrospective analysis from a single institution. Br J Radiol 2017; 90: 20170241.

INTRODUCTION

The National Cancer Institute released a clinical alert and reported higher survival rates after concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer at different stages from the International Federation of Gynecology and Obstetrics (FIGO) Stage IB1 with a relatively good prognosis to Stage IVA with poor prognosis. CCRT has proven effective in the definitive treatment of more advanced-stage diseases.

Regarding a sensitizing agent for CCRT, cisplatin (CDDP) at a dose of 40 mg m⁻² weekly is used globally as a standard regimen. In Japan, a Japanese Gynecologic Oncology Group (JGOG) 1066 Phase II trial of CCRT using a high-dose-rate intracavitary brachytherapy (HDR-ICBT) with CDDP at a dose of 40 mg m⁻² weekly achieved equivalent outcomes to those by global radiotherapy (RT) dose schedules (cumulative linear quadratic equivalent dose, 85 Gy), although with a lower incidence of late toxicity. Although CDDP-based CCRT for locally advanced cervical cancer is accepted as the standard treatment, optimal treatment plan is yet to be established.

In the present study, we retrospectively analyzed data of patients with FIGO Stages IB–IVA carcinoma of the uterine cervix who were primarily treated with CCRT between 2005 and 2013 at University of the Ryukyus Hospital. CCRT using 20 mg m⁻² CDDP for 5 days every 3 weeks was a routine regimen until 2009. Thereafter, we changed the administration schedule of CDDP to weekly regimens of 40 mg m⁻² according to the JGOG 1066 protocol. We analyzed the efficacy of CCRT for squamous-cell carcinoma of the cervix. The present...
retrospective study with a small series of patients might provide useful information for future appropriate treatment strategies.

METHODS AND MATERIALS
We retrospectively analyzed 185 patients with Stages IB–IVA squamous-cell carcinoma of the cervix who were treated with CCRT between 2005 and 2013 at our hospital. None of the patients had received prior treatment. All patients provided written informed consent. Patient charts were reviewed for clinicopathological data. This retrospective study was approved by the institutional review board of our university on 1 September 2016 (#989).

RT was performed as described in a previous study. All patients were treated with anteroposterior and posteroanterior parallel–opposed ports, or with the four-field technique of whole-pelvic (WP) external beam RT (EBRT). A 50-Gy dose of WP-EBRT was delivered in 25 fractions. A centre shield (4-cm wide at the midline) was used in some patients after delivery of the 40-Gy dose. HDR-ICBT was delivered once per week at a fractional dose of 6 Gy which was given one to three times at Point A for a total dose of 6–18 Gy. Boost EBRT doses of 6–20 Gy in one to four fractions were applied to the pelvic walls and/or nodal metastases (≥10 mm in a short-axis diameter) for patients with nodular parametrial involvement. The CCRT regimen consisted of CDDP at 20 mg m$^{-2}$ day$^{-1}$ for 5 days triweekly$^9,^{10}$ or 40 mg m$^{-2}$ weekly,$^7$ administered concomitantly with RT. The Common Terminology Criteria for Adverse Events v. 4.0 and Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria were used for the grading of acute and late toxicities, respectively. Follow-up examinations were performed every month for the first year, every other month for the second year and then every 3–6 months. The survival curves were estimated by Kaplan–Meier method, and the differences were assessed using the log-rank test; a $p$-value of $<0.05$ was considered significant.

RESULTS
Patient characteristics are shown in Table 1. In this retrospective analysis, 185 patients were treated with CCRT in which the triweekly CDDP regimen was used for 110 patients and weekly CDDP regimen for 75 patients. The median follow-up period was 68 months (range: 5–135 months) for the triweekly group and was 36 months (range: 2–88 months) for the weekly group. The median age was 50 years (range: 22–70 years) in the triweekly group and was 50.5 years (range: 28–70 years) in the weekly group. The median total CDDP dose was 200 mg m$^{-2}$ (range: 100–300 mg m$^{-2}$) in the triweekly group and was 200 mg m$^{-2}$ (range: 80–280 mg m$^{-2}$) in the weekly group.

| Clinicopathological variable | Triweekly ($n = 110$) | Weekly ($n = 75$) | $p$-value |
|-----------------------------|----------------------|------------------|-----------|
| Median age (range) (years)  | 50 (22–70)           | 50.5 (28–70)     | 0.274     |
| FIGO stage                  |                      |                  |           |
| IB1                         | 5                    | 11               |           |
| IB2                         | 22                   | 13               |           |
| IIA                         | 7                    | 7                | 0.550     |
| IIB                         | 44                   | 22               |           |
| III                         | 29                   | 21               |           |
| IVA                         | 3                    | 1                |           |
| Median tumour size (range) (mm) | 50 (22–90)           | 49 (20–113)      | 0.320     |
| Pelvic lymph node enlargement |                     |                  |           |
| 0                           | 64                   | 41               |           |
| 1                           | 23                   | 21               |           |
| 2                           | 16                   | 9                | 0.445     |
| ≥3                          | 2                    | 4                |           |
| ND                          | 5                    | 0                |           |
| Median pre-treatment Hb (g dl$^{-1}$) | 11.9 (4.2–14.8)       | 11.5 (4.2–15.7)  | 0.579     |
| Median pre-treatment SCC (ng ml$^{-1}$) | 4.4 (0.8–283)        | 5.6 (0.7–51.8)   | 0.97      |
| Median total CDDP dose (mg m$^{-2}$) | 200 (100–300)        | 200 (80–280)     | 0.129     |
| Median course of chemotherapy (courses) | 2 (1–5)            | 5 (4–6)         | NA        |
| Median overall treatment time (days) | 48 (37–68)        | 51 (45–67)      | 0.135     |
| Median follow-up period (months) | 68 (5–135)         | 36 (2–88)       | <0.0001   |

CDDP, cisplatin; FIGO, the International Federation of Gynecology and Obstetrics; Hb, haemoglobin; SCC, squamous cell carcinoma antigen; NA, not applicable.
(p = 0.129). The median course of triweekly CDDP was two courses (range, 1–5 courses); the median course of weekly CDDP was five courses (range, 4–6 courses); and the median overall treatment time, including HDR-ICBT and boost EBRT, was 48 days (range, 37–68 days) in the triweekly group and 51 days (range, 45–67 days) in the weekly group, respectively (p = 0.135). No significant differences were observed in dose intensity of chemotherapy and the overall treatment time of radiation therapy. No statistically significant differences were observed in the distribution of FIGO staging classification, pre-treatment haemoglobin level, tumour size, lymph node status and serum squamous cell carcinoma antigen level.

The 5-year overall survival (OS) rate in the triweekly and weekly groups were 82.0% and 83.3%, respectively (p = 0.851) (Figure 1); their disease-free survival (DFS) rate was 79.6% and 78.1%, respectively (p = 0.672) (Figure 2). The 5-year local DFS rates in the triweekly and weekly groups were 88.5% and 87.0%, respectively (p = 0.782), and the distant DFS rates were 83.9% and 84.1% (p = 0.938). Regarding recurrence, 24 patients (21.8%) in the triweekly group and 16 patients (21.3%) in the weekly group experienced distant recurrence. No significant difference was observed in the distribution of the site of recurrence between the groups.

Adverse events of CCRT in each group are described in Table 3. In the triweekly group, 56 patients (50.9%) had grade 3/4 leucopenia, which was significantly higher than that of 11 patients (15%) in the weekly group (p < 0.0001). There was no significant difference in other haematologic adverse effects. In non-haematologic adverse events, grade 3/4 nausea/vomiting and diarrhoea were observed in 13 (11.8%) and 16 (14.5%) patients in the triweekly group, respectively while in only 2 (2.6%) and 3 (4%) patients in the weekly group, respectively, and those were significantly higher in the triweekly group. The weekly CDDP regimen for CCRT seems better in patients with FIGO Stage IB–IVA squamous-cell carcinoma of the cervix in our institutions.

Adverse events (Table 4), one patient (0.9%) suffered from grade 4 radiation enterocolitis with required intestinal surgery, and two patients experienced bone fracture (pubic bone and lumbar vertebra) both in the triweekly group on the basis of toxicity criteria of Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer. Grade 2 radiation enterocolitis was observed in six patients (the triweekly group) and three patients (the weekly group), respectively. Grade 2 radiation cystitis was seen in two patients only in the triweekly group. No death due to toxicities occurred during the study period.

**DISCUSSION**

Our retrospective study demonstrates that there is no significant survival difference, including OS, DFS, local DFS and distant DFS, among patients treated with CCRT using 20 mg m⁻² CDDP for 5 days every 3 weeks and CCRT using 40 mg m⁻² CDDP weekly. Although the CDDP dose intensity and overall treatment time are important in CCRT for cervical cancer, no significant difference was observed in CDDP dose intensity and overall treatment time. However, acute adverse events, namely grade 3/4 leukopenia, nausea/vomiting, and diarrhoea were significantly higher in the triweekly group. The weekly CDDP regimen for CCRT seems better in patients with FIGO Stage IB–IVA squamous-cell carcinoma of the cervix in our institutions.

So far, several clinical trials have investigated alternative CDDP dose and dosing schedules to weekly CDDP-based chemoradiation. Einstein et al. reported in their retrospective study that the weekly group had a 3.43 times higher risk of developing acute toxicities than the 5-day group in advanced-stage patients with a significantly shorter 3-year progression-free survival (PFS). Regarding acute toxicity, they mentioned that most of the early toxicities seen in weekly patients were gastrointestinal-related. Significant gastrointestinal-related toxicity in the triweekly group may have been masked by the use of inpatient intravenous fluids and intravenous antiemetic medications.

**Figure 1.** The 5-year overall survival rate in the triweekly and weekly groups were 82.0% and 83.3%, respectively (p = 0.851). CDDP, cisplatin.

**Figure 2.** The 5-year disease-free survival rate in the triweekly and weekly groups were 79.6% and 78.1%, respectively (p = 0.672). CDDP, cisplatin.
In an open-label, randomized trial from the Republic of Korea, 13 104 patients with Stages IIB–IVA cervical cancer were randomly assigned to weekly (weekly CDDP 40 mg m$^{-2}$, six cycles) and triweekly (CDDP 75 mg m$^{-2}$ every 3 weeks, three cycles) chemotheraphy arms during concurrent RT. This study postulated that higher peak concentration of CDDP is more critical in enhancing the synergy of chemoradiation than the weekly CDDP exposure. Also, the high peak concentration might effectively eliminate small clumps of micrometastases, which leads to decrease in local failure and distant metastasis, and thus, to improvement in survival. However, without appropriate pharmacokinetic analysis of peak CDDP levels in both CDDP doses, we cannot clarify that the observed difference is due to higher peak levels of serum CDDP concentration in triweekly administration. Furthermore, the advantages of chemotherapy may not be due to true sensitization but rather by inhibiting tumour repopulation during RT; it is therefore possible that shorter schedules may not require chemotherapy support. 14 The Korean group study 13 suggested that another explanation for this result is that the possible role of CDDP administration during brachytherapy enhances the chemoradiation effect. However, because the third cycle of chemotherapy was delivered on average 10 days before brachytherapy in that study, there was no way of deducing what proportion of the CDDP acted as a radiosensitizer during brachytherapy. Based on the result of the trial, Triweekly Cisplatin-Based Chemoradiation in Locally Advanced Cervical Cancer Phase III randomized clinical trial is ongoing by the Korean Gyencologic Onclogy Group. 15

A randomized Phase 3 trial comparing two CDDP dose schedules (CDDP, 20 mg m$^{-2}$ per day, on Days 1–5 every 21 days, and CDDP, 40 mg m$^{-2}$ per day weekly) concluded that the 21-day CDDP regimen was superior regarding local efficacy and less toxic than the weekly chemotherapy regimen. 16 Owing to the acute toxicity, the proposed CDDP dose was delivered only in 79% of the patients from the triweekly CDDP and in 70% of the patients from the weekly CDDP groups. This underdose in weekly CDDP can be one of the causes of the better results obtained by the triweekly CDDP regimen. However, nodal status was included neither in the randomization criteria nor in the results evaluation. Another limitation of the study is the inclusion of surgery in the therapeutic protocol, deciding optionally on surgery after pre-operative CCRT. These above-mentioned reports recommend triweekly CDDP regimen of CCRT for cervical cancer.

Meanwhile, a randomized clinical trial comparing three monthly cycles of fluorouracil (1000 mg m$^{-2}$ day$^{-1}$ intravenously) plus CDDP (20 mg m$^{-2}$ day$^{-1}$ intravenously) for 5 days with six cycles of weekly CDDP (30 mg m$^{-2}$ intravenously) for CCRT showed that CCRT by weekly CDDP improves compliance with treatment and reduces acute haematological adverse effects without spoiling response and survival rates. 17 An analysis of seven studies between 1995 and 2011 18 and a meta-analysis of five randomized controlled trials between 1995 and 2015 to compare weekly and triweekly CDDP combined RT 19 established that weekly CDDP has a lower risk of haematological toxicity than triweekly CDDP with concurrent RT in the treatment of cervical cancer with no differences in PFS and OS. Clinicians and patients may choose either weekly CDDP or triweekly CDDP combined RT for cervical cancer.

Furthermore, a retrospective analysis comparing CCRT with weekly CDDP with CCRT with monthly CDDP and 5-fluorouracil for two cycles followed by additional consolidation chemotherapy for two cycles with the same regimen 20 showed that there were no statistically significant differences in PFS and OS. They also found that both regimens seemed to have similar

| Site of recurrence | Triweekly (n = 110) | Weekly (n = 75) | $p$-value |
|--------------------|--------------------|----------------|-----------|
| Recurrence (total) | 24 (21.8%)         | 16 (21.3%)     | 0.544     |
| Locoregional       | 5 (20.8%)          | 5 (31.3%)      | 0.482     |
| Distant            | 9 (37.5%)          | 7 (43.8%)      |           |
| Locoregional + distant | 10 (41.7%)   | 4 (25.0%)      |           |

Table 2. Site of recurrence

| Adverse event       | Triweekly (n = 110) | Weekly (n = 75) | $p$-value |
|---------------------|--------------------|----------------|-----------|
|                     | Grade 1/2 | Grade 3/4 | Grade 1/2 | Grade 3/4 |           |
| Leukocytopenia      | 25        | 56       | 15        | 11       | <0.0001   |
| Anaemia             | 50        | 8        | 29        | 6        | 0.533     |
| Thrombocytopenia    | 29        | 13       | 5         | 3        | 0.052     |
| Nausea/vomiting     | 57        | 13       | 15        | 2        | 0.028     |
| Diarrhoea           | 51        | 16       | 26        | 3        | 0.025     |
| Radiation dermatitis| 3         | 1        | 6         | 1        | 0.648     |

Table 3. Acute adverse events
evidence for patients with locally advanced cervical cancer, but the weekly CDDP was better tolerated. Sonoda et al.21 through their retrospective study, also demonstrated that CCRT with both triweekly and weekly CDDP appeared to have similar efficacy for cervical cancer patients, but the toxicities were better tolerated with weekly CCRT. The results from these later four reports are consistent with our analysis.

One of the limitations of our study is that the retrospective nature of the study is inevitable, which can be affected by recall bias and difficulties with data abstraction from charts. The other limitation is that only patients with squamous-cell carcinoma were analyzed in our study, which might affect our results because patients with both squamous-cell carcinoma and adenocarcinoma were investigated in the other reports. Actually, the Gynecologic Oncology Group (GOG) 120 study demonstrates that weekly CDDP at 40 mg m⁻² is equally effective and less toxic than CDDP and 5-fluorouracil regimens.7 However, data from previous Phase I trials did not lead to the choice of weekly CDDP 40 mg m⁻² for Phase III CCRT trials, and the maximum tolerated dose of weekly CDDP during CCRT has not been determined.

Thus, which regimen is better for CCRT in cervical cancer patients remains controversial. However, a recent meta-analysis22 showed that for locally advanced cervical cancer, CCRT with platinum-based doublet regimen contributed to improvements of prognosis, compared with CCRT with weekly CDDP. Therefore, because platinum-based combination therapy should be the preferred treatment over weekly CDDP during CCRT for Stage IB–IVA cervical cancer, we need to develop CCRT with new regimens, such as paclitaxel and CDDP.23,24 Furthermore, CDDP and radiation therapy with or without carboplatin and paclitaxel in patients with locally advanced cervical cancer trial25 and induction chemotherapy plus chemoradiation as first-line treatment for locally advanced cervical cancer trial26 are ongoing. We should consider the additional systemic chemotherapy to CCRT. We believe that a well-designed prospective, randomized trial is necessary to develop a novel CCRT strategy for locally advanced cervical cancer.

ACKNOWLEDGMENTS
The authors thank Enago (www.enago.jp) for the English language review.

REFERENCES

1. National Cancer Institute. Concurrent chemoradiation for cervical cancer. Clinical announcement, Washington, DC February 22; 1999.
2. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144–53. doi: https://doi.org/10.1056/nejm199904153401502
3. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340: 1154–61. doi: https://doi.org/10.1056/nejm199904153401503
4. Morriss M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 1137–43. doi: https://doi.org/10.1056/nejm199904153401501
5. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17: 1339–48. doi: https://doi.org/10.1200/jco.1999.17.5.1339
6. Peters WA 3rd, Liu PJ, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606–13. doi: https://doi.org/10.1200/jco.2000.18.8.1606
7. Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, et al. Cervical Cancer (Vulva Cancer) Committee of Japanese Gynecologic Oncology Group (JGOG). Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Gynecol Oncol 2012; 126: 211–16.
8. Fields AL, Anderson PS, Goldberg GL, Widler S, Beiter I, Sood B, et al. Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix. Gynecol Oncol 1996; 61: 416–22. doi: https://doi.org/10.1006/gyno.1996.0166
9. Hirakawa M, Nagai Y, Inamine M, Kamiyama K, Ogawa K, Toita T, et al. Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Gynecol Oncol 2008; 108: 126–9. doi: https://doi.org/10.1016/j.ygyno.2007.08.091
10. Toita T, Moromizato H, Ogawa K, Kakinohana Y, Machama T, Kanazawa K, et al. Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer. *Gynecol Oncol* 2005; 96: 665–70. doi: https://doi.org/10.1016/j.ygyno.2004.11.046

11. Song S, Rudra S, Hasselle MD, Dorn PL, Mell I K, Mundt AI, et al. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. *Cancer* 2013; 119: 325–31. doi: https://doi.org/10.1002/cncr.22369

12. Einstein MH, Novetsky AP, Garg M, Halpern SM, Huang GS, Glueck A, et al. Survival and toxicity differences between 3-day and weekly cisplatin in patients with locally advanced cervical cancer. *Cancer* 2007; 109: 48–53. doi: https://doi.org/10.1002/cncr.22369

13. Ryu SI, Lee WM, Kim K, Park SI, Kim BI, Kim MH, et al. Randomized clinical trial of weekly vs triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. *Int J Radiat Oncol Biol Phys* 2011; 81: e577–81. doi: https://doi.org/10.1016/j.ijrobp.2011.05.002

14. Jones B, Dale RG. The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy. *Br J Radiol* 2005; 78: 939–44. doi: https://doi.org/10.1259/bjr/40226390

15. Tri-weekly cisplatin based chemoradiation in locally advanced cervical cancer (TACO). [Accessed February 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT01561586?term=taco+kgog&rank=1

16. Nagy VM, Ordeanu C, Coza O, Alin CR, Traila A, Todor N. Randomized phase 3 trial comparing 2 cisplatin dose schedules in 326 patients with locally advanced squamous cell cervical carcinoma: long-term follow-up. *Int J Gynecol Cancer* 2012; 22: 1538–44.

17. Kim YS, Shin SS, Nam JH, Kim YT, Kim YM, Kim JH, et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. *Gynecol Oncol* 2008; 108: 195–200. doi: https://doi.org/10.1016/j.ygyno.2007.09.022

18. Hu Y, Cai ZQ, Su XY. Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy in the treatment of cervical cancer: a meta-analysis result. *Asian Pac J Cancer Prev* 2012; 13: 4301–4. doi: https://doi.org/10.7314/apjcp.2012.13.9.4301

19. Chen X, Zou H, Li H, Lin R, Su M, Zhang W, et al. Weekly vs triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of cervical cancer: a meta-analysis. *Int J Gynecol Cancer* 2017; 27: 344–9. doi: https://doi.org/10.1097/IGC.0000000000001883

20. Kong TW, Chang SI, Paek I, Yoo SC, Yoon JH, Chang KH, et al. Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB–IVA cervical cancer. *J Gynecol Oncol* 2012; 23: 235–41.

21. Sonoda K, Yahata H, Ichinoe A, Okugawa K, Kaneki E, Kawano Y, et al. Retrospective analysis of concurrent chemoradiation with triweekly cisplatin plus 5-fluorouracil versus weekly cisplatin in cervical cancer. *Anticancer Res* 2015; 35: 3447–54.

22. Petrelli F, De Stefani A, Raspagliesi F, Lorusso D, Barniet S. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: A systematic review and meta-analysis. *Gynecol Oncol* 2014; 134: 166–71. doi: https://doi.org/10.1016/j.ygyno.2014.04.049

23. Nagai Y, Toita T, Wakayama A, Nakamoto T, Ooyama T, Tokura A, et al. Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix. *Anticancer Res* 2012; 32: 1475–9.

24. Umayahara K, Takekuma M, Hirashima Y, Noda SE, Ohno T, Miyagi E, et al. Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial. *Gynecol Oncol* 2016; 140: 253–8. doi: https://doi.org/10.1016/j.ygyno.2015.12.008

25. Cisplatin and radiation therapy with or without carboplatin and paclitaxel in patients with locally advanced cervical cancer. [Accessed February 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT01414608

26. Induction chemotherapy plus chemoradiation as first line treatment for locally advanced cervical cancer (INTERLACE). [Accessed February 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT01566240?term=interlace&rank=2